Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 for Prevention of Chemotherapy-Induced Thrombocytopenia
NCT05554913Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing QL0911 with Placebo (2 arms). Primary endpoint: Proportion of patients who had an efficacy response at 42 days. Started Nov 2022; status: completed.
02
Drugs
QL0911
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05554913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554913.